Presentation on theme: "Relapse in Children with ALL By Dr Kaji Protocol for Acute Lymphoblastic Leukemia Relapse IN LANZKOWSKY."— Presentation transcript:
Relapse in Children with ALL By Dr Kaji
Protocol for Acute Lymphoblastic Leukemia Relapse IN LANZKOWSKY
Outcome After First Relapse in Children With Acute Lymphoblastic Leukemia:A Report Based on the Dutch Childhood Oncology Group (DCOG) Rel apse ALL 98 Protocol
Conclusions. Our data suggest the superiority of SCT for early relapse patients. For late relapses a better outcome is achieved with chemotherapy only using the rotational chemotherapy scheme. The most important factor for survival was interval between first CR and occurrence of the first relapse. Pediatr Blood Cancer. 2011;57:210– Wiley-Liss, Inc.
Outcome of Childhood Acute Lymphoblastic Leukemia With Induction Failure Treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F-Protocol
The aim of this prospective study was to evaluate the efficacy and safety of the Japan Association of Childhood Leukemia Study (JACLS) ALL F-protocol on the outcome of childhood ALL with IF. This protocol consists of AML-oriented re-induction and consolidation block therapies followed by allogeneic HCT.
Patients obtaining CR by the end of the first consolidation therapy were scheduled to receive HCT after the second consolidation therapy but before maintenance therapy Maintenance therapy consisted of three alternating blocks for 18 months (Supplemental Table I).
In conclusion, the F-protocol consisting of AML-oriented block therapies followed by allogeneic HCT can improve the prognosis for non-Ph ALL patients with IF. However, to improve the chemotherapy regimen of the F-protocol we plan close MRD monitoring in future studies.
Protocol R16 Treatment element/drug single or daily dose days given Window Topotecan 2.4mg/m2/ IV over 30 min 1- 5 day Induction 1)Dexamethasone 6mg/m2/day po 8-35 day 2)Vincristine 1.5mg/m2/IV 8,15,22,2 3)L.ASP u/m2/IM(or Erwinia if 8,11,13,15,18,20 Previous allergy to E.coll.) 22,25,27,29,32,34 PEg-ASP 2500u/m2/IM 8,15,22,29 4)IT MHA 8,22,36
Consolidation 1)Fludurabine 15mg/m2/IVinf30’ 1,2,3,4 2)Ara-C 2mg/m2/IV 1,2,3,4 Secondary Consolidation (for patients not undergoing bone marrow transplant) 1)VP 16 50mg/m2 po qd 14 days 2)Vincristine 1.5mg/m2(max:2mg)IV 1,8 3)IT (MHA) day1 Continuation Chemotherapy Cycle1: 1)CPM 1gr/m2/IV 1,2 2)Vincristine 1.5mg/m2/IV 1 Cycle2: 1)VP 16 50mg/m2/po d x14day 2)Decadlon 6mg/m2/po 3)VCR 1.5mg/IV(max:2mg) 1-8 Cycle3: 1)HD Mtx 5gr/m2 Infusion for 24 hrs 2)L. Asp 10,000 u/m2/dose IM qodx3 orPEG Asp 2500u/m2/dose IM X 1 Cycle4: 1)HD Ara-C 2g/m2/dose IV over2hrs q12hrx3dose(total:6g/m2) 2)Idarubicin 12mg/m2/IV over30’ 1day( Completion of first dose Ara- C) 3)IT (MHA) on day 1 prior to th HD Ara-C
Standard Continuation Chemotherapy :patients will receive 4-week rotatational cycles of chemotherapy with the following pairs of drugs for total treatment duration of 17 months. Week#1: CPM 300mg/m2/IV VCR 1.5mg/m2/IV Week#2: VM mg/m2/IV Ara-C 300mg/m2/IV Week#3: MTX 40mg/m2/IM or (IV 2 hrs infusion if previous C.R) 6MP 75mg/m2 po q Hs x 7 Week#4: Mtx 40mg/m2/IM or (IV 2 hrs infusion if previous C.R) 6MP 75mg/m2/po q h s x 7 IT(MHA) q8 weeks for patient CNS I and q 4 weeks for patient CNS2/3 who will receive CSI at end